Sign in to view content

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

David M. Brown, MD

Video
Published 2021

Related

Modeling the Effect of Longer-Acting Drugs and Reimbursement Changes
Robert A Diamond, BBA
Updates from the Field
2022
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Steroid vs. Anti-VEGF for Diabetic Macular Edema Prior to Phacoemulsification (STAMP)
Caesar K. Luo, MD, FASRS
On Demand Cases, Courses, and Papers
2021

Category: Pharmacology

See more